Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Muscular Dystrophy Pipeline Review, H2 2014” to its store. The report provides an overview of the Muscular Dystrophy’s therapeutic pipeline.

Muscular Dystrophy Therapeutic Pipeline

Muscular Dystrophy Therapeutic Pipeline

The report " Muscular Dystrophy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dystrophy-pipeline-review-h2-2014-market-report.html .

It also reviews key players involved in the therapeutic development for Muscular Dystrophy and special features on late-stage and discontinued projects. Companies discussed in this Muscular Dystrophy Pipeline Review H2 2014 report include Acceleron Pharma, Inc., aTyr Pharma, Inc., Benitec Biopharma Limited, Bioblast Pharma Ltd., Calzada Limited, Evotec AG, F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., Genethon, Genzyme Corporation, Isis Pharmaceuticals, Inc., Marina Biotech, Inc., Novogen Limited, Prosensa Therapeutics B.V., Prothelia, Inc., SanBio, Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Valentia Biopharma S.L., Zambon Company S.p.A. Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=256231 .

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Table of Contents

List of Tables
Number of Products under Development for Ischemia, H2 2014 15
Number of Products under Development for Ischemia - Comparative Analysis, H2 2014 16
Number of Products under Development by Companies, H2 2014 18
Number of Products under Development by Companies, H2 2014 (Contd..1) 19
Number of Products under Development by Companies, H2 2014 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2014 22
Comparative Analysis by Late Stage Development, H2 2014 23
Comparative Analysis by Clinical Stage Development, H2 2014 24
Comparative Analysis by Early Stage Development, H2 2014 25
Comparative Analysis by Unknown Stage Development, H2 2014 26
Products under Development by Companies, H2 2014 27
Products under Development by Companies, H2 2014 (Contd..1) 28
Products under Development by Companies, H2 2014 (Contd..2) 29
Products under Development by Companies, H2 2014 (Contd..3) 30
Products under Investigation by Universities/Institutes, H2 2014 31
Ischemia - Pipeline by Alize Pharma SAS, H2 2014 32
Ischemia - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 33
Ischemia - Pipeline by AnGes MG, Inc., H2 2014 34
Ischemia - Pipeline by Apceth GmbH & Co. KG, H2 2014 35
Ischemia - Pipeline by Athersys, Inc., H2 2014 36
Ischemia - Pipeline by Baxter International Inc., H2 2014 37
Ischemia - Pipeline by Cellmid Limited, H2 2014 38
Ischemia - Pipeline by CoDa Therapeutics, Inc., H2 2014 39
Ischemia - Pipeline by DNAVEC Corporation, H2 2014 40
Ischemia - Pipeline by GlaxoSmithKline plc, H2 2014 41
Ischemia - Pipeline by Hemostemix Ltd, H2 2014 42
Ischemia - Pipeline by Human Stem Cells Institute, H2 2014 43
Ischemia - Pipeline by IntelliCell BioSciences Inc., H2 2014 44
Ischemia - Pipeline by Juventas Therapeutics, Inc., H2 2014 45
Ischemia - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 46
Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 47
Ischemia - Pipeline by Mast Therapeutics, Inc., H2 2014 48

List of Figures
Number of Products under Development for Ischemia, H2 2014 15
Number of Products under Development for Ischemia - Comparative Analysis, H2 2014 16
Number of Products under Development by Companies, H2 2014 17
Number of Products under Investigation by Universities/Institutes, H2 2014 21
Comparative Analysis by Clinical Stage Development, H2 2014 24
Comparative Analysis by Early Stage Products, H2 2014 25
Assessment by Monotherapy Products, H2 2014 68
Number of Products by Top 10 Targets, H2 2014 69
Number of Products by Stage and Top 10 Targets, H2 2014 69
Number of Products by Top 10 Mechanism of Actions, H2 2014 71
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 71
Number of Products by Top 10 Routes of Administration, H2 2014 73
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 73
Number of Products by Top 10 Molecule Types, H2 2014 75
Number of Products by Stage and Top 10 Molecule Types, H2 2014 75

Explore more reports on Pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@LifeSciReports
Follow >
Sandler Research
since: 04/2014
Like >
Follow us on
Visit website